Wei Hong

Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study

Ziming Li, Yan Wang, Yuping Sun et al. · The Lancet Oncology · 2025 · 37 citations

Medicine, Oncology, Pharmacology +17

SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 study

Ziming Li, Zhengbo Song, Wei Hong et al. · Signal Transduction and Targeted Therapy · 2024 · 35 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial

Kaiyan Chen, Yanjun Xu, Zhiyu Huang et al. · Cancer Medicine · 2023 · 13 citations · Full text

Medicine, Oncology, Pharmacology +16